Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Informazioni relative al progetto

Primavera

ID dell’accordo di sovvenzione: 827213

DOI

10.3030/827213

Progetto chiuso

Data della firma CE 13 Luglio 2018

Data di avvio 1 Agosto 2018

Data di completamento 31 Gennaio 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

NUTRIPHARMA HUNGARIA TAP ES GYOGYSZER ELOALLITO KFT
Hungary

Periodic Reporting for period 1 - Primavera (Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD))

Periodo di rendicontazione: 2018-08-01 al 2019-01-31

Sintesi del contesto e degli obiettivi generali del progetto

Age-related Macular Degeneration (AMD) is a chronic, progressive, sight-threatening disease, caused by the damage of the macula, the small, central area of the retina. People with AMD have difficulty seeing colours, details and later, to read, to drive and to work. The disease causes significant social, medical, and economic burden. Its prevalence (hidden in early stage) is estimated more 8-10% in industrialized countries (EU, USA) for people over 40 years. However, neither screening method is proposed for the early detection of AMD nor its effective treatment has been approved yet. The multivitamin products, found on the market today, have proven low efficiency to supress early stage AMD, and rather expensive compared to their low-effectiveness.
The objective of the Primavera project is the commercialisation of a new medical food for treatment of AMD. Our unique formula, Primavera, is based on immunobiotic compounds, prepared by our innovative technology, and metabolic booster compounds. The formula will expectedly have benefits on both visual functions and retinal alterations in early AMD.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

In the present feasibility study, we examined the technological and market feasibility of Primavera as well as assessed the risks of our project. Based on our experiences and the relevant background scientific results we have drafted a clinical study plan that includes further trials and services that will be the main reference and starting point for the commercialization process. We have updated our preliminary market and competitor assessment and drafted a detailed business plan with professional assistance. Potential risks were covered with adequate contingency plans while our IP protection activities continued.
We concluded that the project is technologically feasible and economically reliable therefore we will continue our efforts to take Primavera to the market and make it a successful treatment that would massively help the society to prevent visual loss and treat early-stage macular degeneration.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Our Primavera product is based on our patented formula that is superior to the state of the art solutions which is proven via several scientific studies. Primavera, contains a mixture of immunobiotic compounds, synergistic vitamins and other supplements. The patented PROSYMBIO TECHNOLOGY® is now granted at EU level, while the grant is pending in China and in the USA, too. Upon the completion of a Phase 2 project it is expected that Primavera becomes market leader as it will provide an effective treatment in preventing visual loss caused by AMD. Patients using ineffective treatments before will perceive improvement in their visual function once taking the Primavera treatment.
The success of the project will contribute to the well-being (well aging) of European citizens. Regarding our company, the success of the project would promote our growth.

primavera-ph1report-image.jpg